HYLORIS PHARMACEUTICALS SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.7 EUR | -1.27% |
|
-2.50% | -8.24% |
| Mar. 14 | Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 | CI |
| Mar. 14 | Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024 |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 245.4 | 446.9 | 310.9 | 357 | 327.6 | - | - |
| Enterprise Value (EV) 1 | 181.6 | 408.7 | 267.8 | 328.1 | 316 | 334.6 | 339.8 |
| P/E ratio | -28.8 x | -38.4 x | -29 x | - | -23.4 x | -17.9 x | 75.5 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1,402 x | 144 x | 105 x | 81 x | 40.2 x | 27.4 x | 5.52 x |
| EV / Revenue | 1,038 x | 132 x | 90.8 x | 74.5 x | 38.8 x | 28 x | 5.73 x |
| EV / EBITDA | -40.4 x | -88.2 x | -25.7 x | -20.6 x | -21.6 x | -27.9 x | 58.6 x |
| EV / FCF | - | - | - | -25.2 x | -21.1 x | -13.9 x | -16.9 x |
| FCF Yield | - | - | - | -3.97% | -4.75% | -7.2% | -5.92% |
| Price to Book | 4.09 x | 9.3 x | 5.73 x | - | 12.7 x | 130 x | 117 x |
| Nbr of stocks (in thousands) | 25,833 | 25,833 | 26,800 | 28,000 | 28,000 | - | - |
| Reference price 2 | 9.500 | 17.30 | 11.60 | 12.75 | 11.70 | 11.70 | 11.70 |
| Announcement Date | 3/9/21 | 3/16/22 | 3/15/23 | 3/14/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.091 | 0.175 | 3.096 | 2.951 | 4.406 | 8.15 | 11.95 | 59.3 |
| EBITDA 1 | - | -4.494 | -4.634 | -10.44 | -15.89 | -14.6 | -12 | 5.8 |
| EBIT 1 | - | -5.075 | -10.54 | -10.64 | -16.24 | -14.3 | -18.35 | 5.05 |
| Operating Margin | - | -2,900% | -340.47% | -360.49% | -368.5% | -175.46% | -153.56% | 8.52% |
| Earnings before Tax (EBT) 1 | - | -7.145 | -11.28 | -10.77 | - | -13 | -23.4 | 0.4 |
| Net income 1 | - | -7.145 | -11.58 | -10.77 | -15.76 | -14.05 | -18.25 | 4.35 |
| Net margin | - | -4,082.86% | -374% | -364.96% | -357.74% | -172.39% | -152.72% | 7.34% |
| EPS 2 | -1.490 | -0.3300 | -0.4500 | -0.4000 | - | -0.5000 | -0.6550 | 0.1550 |
| Free Cash Flow 1 | - | - | - | - | -13.02 | -15 | -24.1 | -20.1 |
| FCF margin | - | - | - | - | -295.6% | -184.05% | -201.67% | -33.9% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 6/16/20 | 3/9/21 | 3/16/22 | 3/15/23 | 3/14/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 |
|---|---|
| Net sales 1 | 1.033 |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income | - |
| Net margin | - |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 9/1/22 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 7 | 12.2 |
| Net Cash position 1 | - | 63.8 | 38.3 | 43 | 28.9 | 11.6 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.5833 x | 2.095 x |
| Free Cash Flow 1 | - | - | - | - | -13 | -15 | -24.1 | -20.1 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 2.320 | 1.860 | 2.020 | - | 0.9200 | 0.0900 | 0.1000 |
| Cash Flow per Share 2 | - | - | - | - | - | -0.5200 | -0.4400 | 0.3300 |
| Capex 1 | - | - | 1.06 | 0.74 | 0.3 | 0.9 | 0.9 | 0.9 |
| Capex / Sales | - | - | 34.27% | 25.04% | 6.76% | 11.04% | 7.53% | 1.52% |
| Announcement Date | 6/16/20 | 3/9/21 | 3/16/22 | 3/15/23 | 3/14/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.7
EUR
Average target price
21.55
EUR
Spread / Average Target
+84.19%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.24% | 350M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HYL Stock
- Financials Hyloris Pharmaceuticals SA
